Exevir Bio’s XVR-012 demonstrates neutralization potency against current SARS-CoV-2 variants

Jan. 15, 2024

Exevir Bio BV has released new data demonstrating that its antibodies are highly potent in neutralizing currently circulating COVID-19 omicron variants.

BioWorld Science Immune Infection Coronavirus

Today's news in brief

BioWorld

BioWorld briefs for March 31, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 31, 2025

CMV history cited in DMD liver death on Sarepta’s Elevidys

BioWorld

Wall Street was weighing the gravity of the death from acute liver failure of a patient who was treated for Duchenne muscular dystrophy (DMD) with Sarepta...

UK government abolishes NHS England

BioWorld MedTech

In a move that surprised many across the health care sector, the U.K. government decided to scrap NHS England, the body which runs the national health service...

Corcept looks to NDA following strong phase III ovarian cancer data

BioWorld

Relacorilant, a cortisol modulator from Corcept Therapeutics Inc., produced new and strong phase III results in treating platinum-resistant ovarian cancer. The...